DC
Therapeutic Areas
Castle Creek Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| D-Fi (dabocemagene autoficel / FCX-007) | Dystrophic Epidermolysis Bullosa (DEB) | Phase 3 |
Leadership Team at Castle Creek Biosciences
MG
Matthew Gantz, M.B.A.
Chairman and Chief Executive Officer
MT
Michael Townsley, R.N.
Head of Quality Assurance
CJ
Christopher J. Larson, M.S., MLS (ASCP)
Vice President, Quality Control
RW
Rhea Williams, M.P.H.
Vice President, Regulatory Affairs
MC
Matthew Crabtree
Vice President, Finance
RB
Robin Blumenthal, Ph.D.
Associate Vice President, Clinical Operations